Provided by Tiger Trade Technology Pte. Ltd.

SIMCERE PHARMA

11.830
+0.8407.64%
Volume:14.74M
Turnover:171.07M
Market Cap:30.38B
PE:18.76
High:11.870
Open:11.520
Low:11.150
Close:10.990
52wk High:14.247
52wk Low:9.070
Shares:2.57B
HK Float Shares:2.57B
Volume Ratio:2.70
T/O Rate:0.57%
Dividend:0.21
Dividend Rate:1.78%
EPS(LYR):0.630
ROE:18.77%
ROA:7.78%
PB:2.76
PE(LYR):18.76
PS:2.98

Loading ...

SIMCERE PHARMA appoints Cherie Mak as Joint Company Secretary following Wai Ling Wong’s resignation

Bulletin Express
·
Mar 25

Simcere Pharma Announces RMB0.18 Final Dividend for FY2025

Bulletin Express
·
Mar 25

Simcere Pharmaceutical appoints Cherie Mak as joint company secretary; Wong Wai Ling resigns effective March 25, 2026

Reuters
·
Mar 25

Simcere Pharmaceutical - Target Co Refers to Shanghai Simcere Diagnostic Technology

THOMSON REUTERS
·
Mar 25

Simcere Pharmaceutical - Unit to Buy Entire Stake in Target Company for RMB30.8 Mln

THOMSON REUTERS
·
Mar 25

Simcere Pharmaceutical proposes bylaw amendments; adoption of new articles advances to shareholder vote at AGM

Reuters
·
Mar 25

Simcere Pharmaceutical - Zhou Yunshu Appointed as Chief Executive Officer

THOMSON REUTERS
·
Mar 25

Simcere Pharmaceutical appoints Zhou Yunshu CEO effective March 25, 2026; Ren Jinsheng steps down as CEO and stays chairman

Reuters
·
Mar 25

Simcere Pharmaceutical FY2025 final dividend is proposed at RMB 0.18 per share; payment date set for 13 July 2026

Reuters
·
Mar 25

Simcere Pharmaceutical FY2025 profit attributable to equity shareholders jumps 86.2% to RMB1.3 billion; revenue increases 16.5% to RMB7.7 billion

Reuters
·
Mar 25

Simcere Pharmaceutical - Final Dividend of RMB0.18 per Share

THOMSON REUTERS
·
Mar 25

Simcere Pharmaceutical FY2025 revenue rises to CNY 8 billion; Ko Weike (daridorexant) gains China approval for adult insomnia

Reuters
·
Mar 25

Simcere Pharma (02096.HK) Posts 80% Complete Response in Phase I/II Study of SIM0237 for High-Risk NMIBC

Bulletin Express
·
Mar 17

SIMCERE PHARMA (02096) Unveils Phase I/II Clinical Trial Data for SIM0237 in Bladder Cancer at 2026 European Urology Conference

Stock News
·
Mar 17

Simcere’s SIM0237 NMIBC trial reports 80% complete response rate in CIS patients

Reuters
·
Mar 17

Simcere Pharmaceutical to Hold Board Meeting to Approve Annual Results and Consider Final Dividend

Reuters
·
Mar 13

A Look At Simcere Pharmaceutical Group (SEHK:2096) Valuation As 2025 Growth Guidance Draws Investor Focus

Simply Wall St.
·
Mar 11